Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Short-term Investments (2019 - 2025)

Historic Short-term Investments for Nurix Therapeutics (NRIX) over the last 7 years, with Q4 2025 value amounting to $346.0 million.

  • Nurix Therapeutics' Short-term Investments fell 3074.65% to $346.0 million in Q4 2025 from the same period last year, while for Nov 2025 it was $346.0 million, marking a year-over-year decrease of 3074.65%. This contributed to the annual value of $346.0 million for FY2025, which is 3074.65% down from last year.
  • Latest data reveals that Nurix Therapeutics reported Short-term Investments of $346.0 million as of Q4 2025, which was down 3074.65% from $350.4 million recorded in Q3 2025.
  • Nurix Therapeutics' 5-year Short-term Investments high stood at $499.6 million for Q4 2024, and its period low was $176.7 million during Q1 2021.
  • Moreover, its 5-year median value for Short-term Investments was $244.1 million (2022), whereas its average is $281.2 million.
  • The largest annual percentage gain for Nurix Therapeutics' Short-term Investments in the last 5 years was 14398.19% (2025), contrasted with its biggest fall of 3074.65% (2025).
  • Over the past 5 years, Nurix Therapeutics' Short-term Investments (Quarter) stood at $215.2 million in 2021, then grew by 13.69% to $244.7 million in 2022, then decreased by 4.65% to $233.3 million in 2023, then surged by 114.16% to $499.6 million in 2024, then crashed by 30.75% to $346.0 million in 2025.
  • Its last three reported values are $346.0 million in Q4 2025, $350.4 million for Q3 2025, and $401.5 million during Q2 2025.